| Bioactivity | LY 233053 is a potent and competitive NMDA-receptor antagonist with anticonvulsant and antiepileptic efficacy[1][2]. |
| In Vivo | LY 233053 (0.5 和 5 mg/kg) 对电惊厥阈值没有影响，但增强了抗癫痫药物的抗惊厥作用[1]。LY 233053 (5mg/kg) 与卡马西平、二苯基苯妥英或苯巴比妥联合使用可提供 50% 的最大电击保护，但会导致长期记忆损伤[1]。LY233053 (静脉团注，100mg/kg; 在可逆脊髓缺血后 5、30 或 60 分钟内给药) 对限制缺血性损伤是有效的，但如果在新西兰大白兔损伤后 60 分钟内不开始治疗，保护作用就会丧失[2]。 |
| Name | LY 233053 |
| CAS | 125546-04-5 |
| Formula | C8H13N5O2 |
| Molar Mass | 211.22 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. 1.K K Borowicz, et al. Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia. 1996 Jul;37(7):618-24. [2]. K P Madden, et al. Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J Neurosurg. 1992 Jan;76(1):106-10. |